C12251: Diagnostic Protein Biomarkers For Pancreatic CancerNovelty:
This technology comprises the identification of three protein biomarkers, highly expressed in pancreatic cancer compared to normal pancreatic cells.
Value Proposition:
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the US. Thus there is an unmet need for diagnostic markers in pancreatic cancer. Current markers are not very reliable. This invention provides three biomarkers strongly expressed in pancreatic cancer where as weakly or not expressed at all in pancreatic normal duct cells. These proteins are targets of clinically relevant antibody response induced with vaccination. Other advantages include:
• Novel targets for treatment intervention
• Markers for early diagnosis
• Can be used to monitor response to immunotherapy
• Potential as drug development targets
Technical Details:
Johns Hopkins researchers have identified protein biomarkers that are expressed at higher levels in pancreatic ductal adenocarcinoma cells compared to normal pancreatic cells. These markers were identified in patients undergoing a vaccine treatment to pancreatic cancer using a high throughput proteomic approach. Studies showed that expression levels and mis-localization of these markers correlate with increased cancer development.
Looking for Partners:
To develop & commercialize this technology as a pancreatic cancer diagnostic panel.
Stage of Development:
Disovery/ Pre-Clinical
Data Availability:
Human pancreatic cancer cell line, Vaccine tumor cell line
Publications/Associated Cases:
Not at this time.
